Incident Report
Subform I: General Information
1. Report Type.
New incident report
Incident Report Number: 2014-0405
2. Registrant Information.
Registrant Reference Number: 2014CK030
Registrant Name (Full Legal Name no abbreviations): Bayer Inc
Address: 77 Belfield Rd
City: Toronto
Prov / State: ON
Country: Canada
Postal Code: M9W 1G6
3. Select the appropriate subform(s) for the incident.
Domestic Animal
4. Date registrant was first informed of the incident.
16-JAN-14
5. Location of incident.
Country: UNITED STATES
Prov / State: UNKNOWN
6. Date incident was first observed.
15-AUG-13
Product Description
7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.
Active(s)
PMRA Registration No.
PMRA Submission No.
EPA Registration No. 11556-127
Product Name: Advantage II large dog
- Active Ingredient(s)
- IMIDACLOPRID
- Guarantee/concentration 9.1 %
- PYRIPROXYFEN
- Guarantee/concentration .46 %
7. b) Type of formulation.
Liquid
Application Information
8. Product was applied?
Yes
9. Application Rate.
2.5
Units: mL
10. Site pesticide was applied to (select all that apply).
Site: Animal / Usage sur un animal domestique
11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).
On an unknown date in August 2012, a 10.5 year old, male, Retriever Labrador (No Description) canine, in fair condition, with history of seizures controlled with an unknown seizure medication, was administered 1 tube of Advantage II Large Dog (Imidacloprid-Pyriproxyfen) once topically by the owner
To be determined by Registrant
12. In your opinion, was the product used according to the label instructions?
Unknown
Subform III: Domestic Animal Incident Report
1. Source of Report
Animal's Owner
2. Type of animal affected
Dog / Chien
3. Breed
Labrador retriever
4. Number of animals affected
1
5. Sex
Male
6. Age (provide a range if necessary )
10.5
7. Weight (provide a range if necessary )
Unknown
8. Route(s) of exposure
Skin
9. What was the length of exposure?
>1 wk <=1 mo / > 1 sem < = 1 mois
10. Time between exposure and onset of symptoms
Unknown / Inconnu
11. List all symptoms
System
- Nervous and Muscular Systems
- Symptom - Seizure
- Symptom - Ataxia
- Eye
- Symptom - Blindness (permanent)
12. How long did the symptoms last?
Unknown / Inconnu
13. Was medical treatment provided? Provide details in question 17.
No
14. a) Was the animal hospitalized?
No
14. b) How long was the animal hospitalized?
15. Outcome of the incident
Died
16. How was the animal exposed?
Treatment / Traitement
17. Provide any additional details about the incident
(eg. description of the frequency and severity of the symptoms
On approximately 15-Aug-2013 the dog exhibited seizures that became progressively worse. The dog later developed ataxia, weight loss, and blindness. On 05-Sep-2013 the dog passed away. No treatments or diagnostics were performed. No necropsy was performed.The owner initially contacted Bayer Animal Health to seek advise on application of the product and not to report the death of this pet.
To be determined by Registrant
18. Severity classification (if there is more than 1 possible classification
Death
19. Provide supplemental information here
The information regarding the death of the dog was casually provided during an inquiry. Seizures resulting in reported signs and eventually death are not anticipated with topical administration of Advantage II. From a toxicological point of view, imidacloprid or pyriproxyfen do not have the potential to provoke seizures in vertebrates. Time to onset of death after last exposure with more than one year. Medical history with seizures and treated for. Cause of death was probably due to progression of seizures in this geriatric dog. A relation to the product is therefore unlikely.